Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle
Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle
Authorised
- Penethamate hydriodide
- Framycetin sulfate
- Benethamine penicillin
Product identification
Medicine name:
Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle
Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle
Active substance:
- Penethamate hydriodide
- Framycetin sulfate
- Benethamine penicillin
Target species:
-
Cattle
Route of administration:
-
Intramammary use
Product details
Active substance and strength:
-
Penethamate hydriodide100.00milligram(s)1.00Syringe
-
Framycetin sulfate100.00milligram(s)1.00Syringe
-
Benethamine penicillin280.00milligram(s)1.00Syringe
Pharmaceutical form:
-
Intramammary suspension
Withdrawal period by route of administration:
-
Intramammary use
- Cattle
-
Meat and offal10day
-
Milk37day
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QJ51RC25
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Ireland
Package description:
- Cardboard box or plastic container containing 20 single useintramammary syringes and 20 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.
- Cardboard box or plastic container containing 60 single useintramammary syringes and 60 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.
- Cardboard box or plastic container containing 120 single useintramammary syringes and 120 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
- Lohmann Pharma Herstellung GmbH
- Haupt Pharma Latina S.r.l.
Responsible authority:
- Health Products Regulatory Authority
Authorisation number:
- VPA10454/001/001
Date of authorisation status change:
Reference member state:
-
Ireland
Procedure number:
- IE/V/0271/001
Concerned member states:
-
Austria
-
Belgium
-
Bulgaria
-
Cyprus
-
Czechia
-
Estonia
-
France
-
Germany
-
Greece
-
Hungary
-
Latvia
-
Lithuania
-
Netherlands
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
English (PDF)
Download Published on: 11/02/2022
How useful was this page?: